Bellicum Pharma announces Rivo-cel™ achieves primary endpoint in pediatric registrational
Bellicum announced the primary endpoint of event free survival at 180 days in its BP-004 European registration trial for rivo-cel (rivogenlecleucel) has been achieved. Data from this trial will form the basis of an anticipated submission of European MAAs for rivo-cel and rimiducid. July 08, 2019